Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.053
Neutral
RSI(14)
49.292
Neutral
STOCH(KDJ)(9,3,3)
59.425
Sell
ATR(14)
0.584
High Vlolatility
CCI(14)
-3.292
Neutral
Williams %R
63.158
Sell
TRIX(12,20)
0.686
Sell
StochRSI(14)
0.000
Sell
Search
Precision BioSciences Inc
DTILAdd to Watchlist
7.270USD
-0.840-10.36%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
187.58MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Precision BioSciences Inc
Currency: USD Updated: 2026-05-15Key Insights
Precision BioSciences Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 95 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 32.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precision BioSciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Precision BioSciences Inc Highlights
StrengthsRisks
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Growing
The company is in a growing phase, with the latest annual income totaling USD 34.26M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -3.46, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 15.71M shares, increasing 16.10% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 326.48K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.22.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
32.000
Target Price
+294.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Precision BioSciences Inc is 5.67, ranking 329 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 10.84M, representing a year-over-year increase of 37272.41%, while its net profit experienced a year-over-year increase of 10.33%.
Score
Financials
5.99
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.24
Operational Efficiency
2.84
Growth Potential
5.18
Shareholder Returns
7.08
Precision BioSciences Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Precision BioSciences Inc is 8.57, ranking 36 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.46, which is -263.33% below the recent high of 5.65 and -14.72% above the recent low of -3.97.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 95/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Precision BioSciences Inc is 9.00, ranking 17 out of 382 in the Biotechnology & Medical Research industry. The average price target is 25.50, with a high of 60.00 and a low of 19.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
32.000
Target Price
+294.57%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Precision BioSciences Inc
DTIL
4
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Precision BioSciences Inc is 6.57, ranking 221 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.41 and the support level at 6.32, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
7.956
Sell
MA10
7.755
Sell
MA20
7.515
Sell
MA50
6.764
Buy
MA100
5.423
Buy
MA200
5.421
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Precision BioSciences Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 60.88%, representing a quarter-over-quarter increase of 64.56%. The largest institutional shareholder is James Simons, holding a total of 326.48K shares, representing 1.27% of shares outstanding, with 69.09% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Precision BioSciences Inc is 2.44, ranking 217 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.32
VaR
+7.88%
240-Day Maximum Drawdown
+58.54%
240-Day Volatility
+83.20%
Return
Best Daily Return
60 days
+13.59%
120 days
+13.59%
5 years
+29.63%
Worst Daily Return
60 days
-10.36%
120 days
-10.36%
5 years
-31.24%
Sharpe Ratio
60 days
+3.69
120 days
+1.56
5 years
-0.57
Risk Assessment
Maximum Drawdown
240 days
+58.54%
3 years
+82.84%
5 years
+99.16%
Return-to-Drawdown Ratio
240 days
+0.76
3 years
-0.22
5 years
-0.20
Skewness
240 days
+0.24
3 years
+0.67
5 years
+0.58
Volatility
Realised Volatility
240 days
+83.20%
5 years
+87.66%
Standardised True Range
240 days
+5.29%
5 years
+46.81%
Downside Risk-Adjusted Return
120 days
+280.97%
240 days
+280.97%
Maximum Daily Upside Volatility
60 days
+65.03%
Maximum Daily Downside Volatility
60 days
+52.77%
Liquidity
Average Turnover Rate
60 days
+2.32%
120 days
+2.10%
5 years
--
Turnover Deviation
20 days
-21.62%
60 days
+3.17%
120 days
-6.78%
Peer Comparison
Biotechnology & Medical Research
Precision BioSciences Inc
DTIL
6.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
